0750 GMT - Galderma posted strong first-quarter sales figures that increase confidence in its full-year guidance, RBC Capital Markets analysts Alistair Campbell and Charles Weston say in a research note. The Swiss skincare company reiterated its guidance for net sales growth at 10-12% at constant currency. However, it now includes the impact of recently announced U.S. tariffs on its fillers and biostimulators business in the U.S., which accounts for around 9% of total sales, the analysts say. Shares trade 6.2% higher at 85.60 Swiss francs. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 03:51 ET (07:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.